|Bid||43.40 x 300|
|Ask||44.99 x 100|
|Day's Range||42.93 - 46.84|
|52 Week Range||19.80 - 57.80|
|PE Ratio (TTM)||25.45|
|Forward Dividend & Yield||1.00 (2.15%)|
|1y Target Est||N/A|
For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...
Expedia (EXPE) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
High-growth may be important to some investors, whereas steady dividend payments or great value for money may be a deciding factor for others. There are many factors that make upRead More...
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
Wright Medical (WMGI) delivers promising Q4 results on the back of strength in its flagship Upper Extremities segment, despite declining international revenues of the Lower Extremities.